Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...

Wegovy (semaglutide) is a brand-name subcutaneous injection (shot) prescribed for weight loss and to lower the risk of cardiovascular problems in some people. As with other drugs, Wegovy can cause ...

Wegovy comes as a solution inside prefilled, single-dose pens. It’s given as a subcutaneous injection. You’ll inject a Wegovy dose once per week, on the same day each week. You can take your ...

Wegovy comes as a liquid solution inside a prefilled single-dose pen for subcutaneous injection (an injection under your skin). For more details on Wegovy, including limitations of use ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Novo is also testing a subcutaneous form of amycretin that, like Wegovy, would be delivered by regular injection. The early stage trial is ongoing and data is expected to be released in 2025.

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...